Chinese Biosimilars Firm 3SBio Reports Positive Second Quarter
This article was originally published in PharmAsia News
Executive Summary
3SBio, the first Chinese biotechnology company to list on NASDAQ, reported strong second-quarter earnings for its lead EPO and thrombopoietin products and is on track to launch a pre-filled syringe EPO product in China by year-end, the firm announced Aug. 8